argenx SE (NASDAQ:ARGX) Receives $530.74 Consensus Price Target from Brokerages

Shares of argenx SE (NASDAQ:ARGX) have earned an average rating of “Moderate Buy” from the twenty-one ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, fourteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $528.16.

Several research firms have recently commented on ARGX. Robert W. Baird cut their price objective on argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a report on Friday, March 1st. Truist Financial increased their price objective on argenx from $370.00 to $440.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. HC Wainwright reissued a “buy” rating and issued a $451.00 price objective on shares of argenx in a report on Thursday. Piper Sandler raised their price target on argenx from $518.00 to $522.00 and gave the company an “overweight” rating in a report on Friday, January 26th. Finally, Wells Fargo & Company raised their price target on argenx from $472.00 to $478.00 and gave the company an “overweight” rating in a report on Tuesday, February 20th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ARGX. Capital World Investors increased its position in shares of argenx by 37.0% in the fourth quarter. Capital World Investors now owns 1,961,202 shares of the company’s stock worth $746,099,000 after purchasing an additional 530,181 shares during the period. Massachusetts Financial Services Co. MA grew its position in argenx by 339.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 581,586 shares of the company’s stock valued at $285,925,000 after acquiring an additional 449,151 shares during the last quarter. Morgan Stanley grew its position in argenx by 236.9% in the fourth quarter. Morgan Stanley now owns 630,330 shares of the company’s stock valued at $238,788,000 after acquiring an additional 443,217 shares during the last quarter. Jennison Associates LLC grew its position in argenx by 32.2% in the third quarter. Jennison Associates LLC now owns 1,511,745 shares of the company’s stock valued at $743,219,000 after acquiring an additional 368,367 shares during the last quarter. Finally, Artisan Partners Limited Partnership grew its position in argenx by 12.2% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,174,477 shares of the company’s stock valued at $1,207,666,000 after acquiring an additional 346,178 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Trading Up 0.5 %

NASDAQ ARGX opened at $360.23 on Wednesday. The company has a market cap of $21.36 billion, a PE ratio of -70.08 and a beta of 0.65. argenx has a 12 month low of $327.73 and a 12 month high of $550.76. The stock has a 50 day moving average of $387.43 and a 200-day moving average of $420.93.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The company had revenue of $417.84 million during the quarter, compared to analyst estimates of $378.60 million. argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. During the same period in the previous year, the company posted ($0.70) EPS. As a group, sell-side analysts predict that argenx will post -2.11 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.